News | June 12, 2022
Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Tislelizumab is now approved in nine indications in China
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Based on a post hoc analysis, fewer required respiratory interventions
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Innate to receive $5M milestone payment from AstraZeneca
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Subscribe To Our Newsletter & Stay Updated
